Resistin, Adiponectin, and Risk of Heart FailureThe Framingham Offspring Study
David S. Frankel, MD*,
Ramachandran S. Vasan, MD , ,
Ralph B. D'Agostino, Sr, PhD,
Emelia J. Benjamin, MD, ScM,, ,
Daniel Levy, MD,||,
Thomas J. Wang, MD,¶ and
James B. Meigs, MD, MPH,#,*
* Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
Framingham Heart Study, Framingham, Massachusetts
Department of Medicine, School of Medicine, Boston University, Boston, Massachusetts
Department of Epidemiology, School of Public Health, Boston University, Boston, Massachusetts
|| National Heart, Lung, and Blood Institute, Bethesda, Maryland
¶ Division of Cardiology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
# General Medicine Division, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
View larger version (25K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Heart Failure Free Survival by Adipokine Concentration
(A and B) Kaplan-Meier curves are shown for survival free of heart failure according to baseline thirds of resistin and adiponectin (log-rank p < 0.0001 for resistin, p = 0.7 for adiponectin). (C and D) Dose-response relationships between resistin and adiponectin and heart failure are illustrated with generalized additive Cox models (maximally adjusted as in Model 3E) (Table 3) using penalized splines. Dashed lines represent 95% confidence limits of the resulting hazard ratios. (E and F) Histograms illustrate the frequency distribution of study subjects across concentrations of resistin and adiponectin. There is a linear dose-response relationship of resistin with risk of heart failure across the range where the greatest number of subjects contribute information on resistin concentration.
|
|
|
